|
 The requirement that patients be told that the effects of abortion
pills may be undone by using high doses of a hormone was the most
hotly contested provision during legislative debate.
Supporters said there was ample evidence the reversal was possible
if acted upon quickly, although they provided no peer-reviewed
studies in support of their position.
Critics called the argument "junk science."
The bill cleared the Republican-controlled Legislature last week,
largely along party lines.
In December, the U.S. Supreme Court blocked Arizona from enforcing a
state law that restricted access to abortion-inducing drugs by
prohibiting off-label uses of RU-486, known as the "abortion pill."
In a statement regarding the bill's provision barring women from
buying coverage on the federal healthcare exchange that includes
abortion, Ducey said: "The American people overwhelmingly oppose
taxpayer funding of abortions, and it's no different in Arizona,
where we have long-standing policy against subsidizing them with
public dollars."
Opponents said there was no proof public dollars had been used for
the elective procedures and called the measure an overreach.
Bryan Howard, president of Planned Parenthood Advocates of Arizona,
said the bill's signing again put Arizona in a bad light for
"interfering in the medical decisions of women," and vowed to keep
opposing the law through "all of our options, including litigation."
[to top of second column] |
Supporters of the measure, which exempts cases of incest, rape and
life-saving situations, said the ban was needed because many
individuals insured through the federally run exchange set up under
the Affordable Care Act, known as Obamacare, received government
subsidies.
"Countless more lives will be saved, and women spared a lifetime of
regret," said Cathi Herrod, president of the conservative Center for
Arizona Policy.
(Reporting by David Schwartz in Phoenix; Writing by Eric M. Johnson;
Editing by Eric Beech and Peter Cooney)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
